Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

Cited In for PubMed (Select 19445944)

1.

Prevalence and predictors of hospitalization in Crohn's disease in a prospective population-based inception cohort from 2000-2012.

Golovics PA, Lakatos L, Mandel MD, Lovasz BD, Vegh Z, Kurti Z, Szita I, Kiss LS, Pandur T, Lakatos PL.

World J Gastroenterol. 2015 Jun 21;21(23):7272-80. doi: 10.3748/wjg.v21.i23.7272.

2.

Impact of medical therapy on patients with Crohn's disease requiring surgical resection.

Fu YT, Hong T, Round A, Bressler B.

World J Gastroenterol. 2014 Sep 7;20(33):11808-14. doi: 10.3748/wjg.v20.i33.11808.

3.

Current approaches to the management of new-onset ulcerative colitis.

Marchioni Beery R, Kane S.

Clin Exp Gastroenterol. 2014 May 9;7:111-32. doi: 10.2147/CEG.S35942. eCollection 2014. Review.

4.

Inflammatory bowel disease course in Crohn's disease: is the natural history changing?

Golovics PA, Mandel MD, Lovasz BD, Lakatos PL.

World J Gastroenterol. 2014 Mar 28;20(12):3198-207. doi: 10.3748/wjg.v20.i12.3198. Review.

5.

Patterns of 6-mercaptopurine and azathioprine maintenance therapy among a cohort of commercially insured individuals diagnosed with Crohn's disease in the United States.

Lund JL, Cook SF, Allen JK, Carroll CF, Kappelman MD.

Clin Epidemiol. 2013 Dec 6;5:501-12. doi: 10.2147/CLEP.S51625. eCollection 2013.

6.

Has the risk of colorectal cancer in inflammatory bowel disease decreased?

Andersen NN, Jess T.

World J Gastroenterol. 2013 Nov 21;19(43):7561-8. doi: 10.3748/wjg.v19.i43.7561. Review.

7.

The impact of thiopurines on surgical outcomes in inflammatory bowel disease: do they make a difference?

Chhaya V, Pollok R.

F1000Prime Rep. 2013 Nov 1;5:50. doi: 10.12703/P5-50. eCollection 2013. Review.

8.

Interventions and targets aimed at improving quality in inflammatory bowel disease ambulatory care.

Weizman AV, Nguyen GC.

World J Gastroenterol. 2013 Oct 14;19(38):6375-82. doi: 10.3748/wjg.v19.i38.6375. Review.

9.

Quality of care delivered to hospitalized inflammatory bowel disease patients.

Weizman AV, Nguyen GC.

World J Gastroenterol. 2013 Oct 14;19(38):6360-6. doi: 10.3748/wjg.v19.i38.6360. Review.

10.

Effect of azathioprine or mesalazine therapy on incidence of re-hospitalization in sub-occlusive ileocecal Crohn's disease patients.

de Souza GS, Vidigal FM, Chebli LA, da Rocha Ribeiro TC, Furtado MC, de Lima Pace FH, de Miranda Chaves LD, de Oliveira Zanini KA, Gaburri PD, de Azevedo Lucca F, Zanini A, Ribeiro LC, Chebli JM.

Med Sci Monit. 2013 Aug 30;19:716-22. doi: 10.12659/MSM.889196.

11.

Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis.

Bewtra M, Kaiser LM, TenHave T, Lewis JD.

Inflamm Bowel Dis. 2013 Mar;19(3):599-613. doi: 10.1097/MIB.0b013e31827f27ae.

12.

Race and inflammatory bowel disease in an urban healthcare system.

Sewell JL, Inadomi JM, Yee HF Jr.

Dig Dis Sci. 2010 Dec;55(12):3479-87. doi: 10.1007/s10620-010-1442-8. Epub 2010 Oct 9.

13.

Risk of diagnosed fractures in children with inflammatory bowel diseases.

Kappelman MD, Galanko JA, Porter CQ, Sandler RS.

Inflamm Bowel Dis. 2011 May;17(5):1125-30. doi: 10.1002/ibd.21472. Epub 2010 Sep 24.

14.

Racial disparities in utilization of specialist care and medications in inflammatory bowel disease.

Nguyen GC, LaVeist TA, Harris ML, Wang MH, Datta LW, Brant SR.

Am J Gastroenterol. 2010 Oct;105(10):2202-8. doi: 10.1038/ajg.2010.202. Epub 2010 May 18.

15.

Blood transfusion for the treatment of acute anaemia in inflammatory bowel disease and other digestive diseases.

García-Erce JA, Gomollón F, Muñoz M.

World J Gastroenterol. 2009 Oct 7;15(37):4686-94. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk